{"title":"Fourth Nerve Palsy as the Presenting Manifestation of Giant Cell Arteritis.","authors":"Samira Jafari, Jonathan A Micieli","doi":"10.1017/cjn.2024.344","DOIUrl":"10.1017/cjn.2024.344","url":null,"abstract":"","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-2"},"PeriodicalIF":2.9,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Judy Illes, Susan Boehnke, Jennifer A Chandler, Shirley Fecteau, Pauline Gaprielian, Nir Lipsman, Graeme Moffat, Amy Zarzeczny
{"title":"Principles and Priorities for Responsible Innovation in Neurotechnology for Canada.","authors":"Judy Illes, Susan Boehnke, Jennifer A Chandler, Shirley Fecteau, Pauline Gaprielian, Nir Lipsman, Graeme Moffat, Amy Zarzeczny","doi":"10.1017/cjn.2024.322","DOIUrl":"https://doi.org/10.1017/cjn.2024.322","url":null,"abstract":"","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-4"},"PeriodicalIF":2.9,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pharmacist-Implemented Self-Management Module in Multiple Sclerosis Patients: A Randomized Controlled Trial.","authors":"Cansu Goncuoglu, Pinar Acar Ozen, Merve Kasikci, Asli Tuncer, Aygin Bayraktar Ekincioglu","doi":"10.1017/cjn.2024.345","DOIUrl":"10.1017/cjn.2024.345","url":null,"abstract":"<p><strong>Background: </strong>Self-management practices can contribute to the lives of patients with multiple sclerosis. The aim of this study is to improve patients' self-management abilities through a multidisciplinary developed module.</p><p><strong>Methods: </strong>This prospective, randomized controlled trial was conducted between January 2020 and November 2021 at a university hospital in Ankara, Turkiye. The self-management module was implemented by a clinical pharmacist with the aim of enhancing self-management capabilities through an educational approach, with a focus on medication adherence, management of drug-related problems, follow-ups and self-directed activities. The intervention group completed the self-management module, while the control group received usual outpatient care. To evaluate the impact of the module, the Multiple Sclerosis Self-Management Revised scale was administered to the patients. Interviews were conducted at 4-month intervals.</p><p><strong>Results: </strong>Study (<i>n</i> = 102) and control group (<i>n</i> = 98) patients were followed up for 8 months, and the median duration of intervention was 11 minutes. The mean (± SD) self-management scores of the study group increased from 68.9 (± 9.3) to 79.0 (± 9.4) at the end of the interviews, and this increase was found to be significant compared to the control group (<i>p</i> < 0.001). The self-management module has been shown to improve self-management, medication adherence, perception of care and patient engagement in treatment (<i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>This single-center randomized controlled trial suggests that a pharmacist-implemented self-management module increased patient engagement and medication adherence. The self-management interventions could be tailored to groups that tend to have lower self-management abilities, such as older individuals, and those who have lower educational attainment, health engagement or medication adherence.</p>","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-10"},"PeriodicalIF":2.9,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Madeline A Komar, Sultan Yahya, Crystal Fong, Zehra Isik Hasiloglu, Nazir Khan
{"title":"Non-ischemic Cerebral Enhancing (NICE) Lesions: A Rare Complication of Treating Intracranial Aneurysms with Endovascular Coiling.","authors":"Madeline A Komar, Sultan Yahya, Crystal Fong, Zehra Isik Hasiloglu, Nazir Khan","doi":"10.1017/cjn.2024.320","DOIUrl":"https://doi.org/10.1017/cjn.2024.320","url":null,"abstract":"","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-2"},"PeriodicalIF":2.9,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yasmine Hoydonckx, Philip Peng, Charlotte Vydt, Farnaz Amoozegar
{"title":"The Challenges of Patients with Spinal CSF Leaks in Canada: A Cross-Sectional Online Survey.","authors":"Yasmine Hoydonckx, Philip Peng, Charlotte Vydt, Farnaz Amoozegar","doi":"10.1017/cjn.2024.315","DOIUrl":"https://doi.org/10.1017/cjn.2024.315","url":null,"abstract":"<p><strong>Background: </strong>Spinal CSF leak can cause disabling headaches and neurological symptoms. Lack of awareness, diagnostic delay and treatment inconsistencies affect the quality of CSF leak care globally. This is the first study aiming to identify and assess these challenges in Canada.</p><p><strong>Methods: </strong>A cross-sectional online survey of Canadian patients with spinal CSF leak was designed in collaboration with Spinal CSF Leak Canada, including questions on demographics, headache condition, investigations, treatments, quality of life, financial consequences and out-of-country care.</p><p><strong>Results: </strong>The survey captured 103 respondents with confirmed spinal CSF leak diagnosis, of whom 56% were still suffering. The majority were female (80%), most being highly educated, with a mean age of 41.8 (SD: 10.37) years at the time of diagnosis. Inconsistencies in care resulted in variable durations for obtaining diagnosis and treatment. The majority of respondents (88%) had seen multiple physicians, and only 50% had seen a CSF leak specialist. Invasive imaging was not performed in 43%. CSF leak relapse after initial successful treatment occurred frequently (43%). The incidence of rebound intracranial hypertension was high (52.5%), and the treatment was difficult to access (77%). Out-of-country care was common (28%), and the impact on financial health was omnipresent (81.5%).</p><p><strong>Conclusion: </strong>The survey demonstrates significant gaps in spinal CSF leak care in Canada, similar to global observations. Lack of awareness and access, delayed care, and inconsistencies in investigations and management are common. Spinal CSF leak significantly impacts patients' physical, mental and financial well-being. Increased awareness, referral pathways and standardized treatment algorithms are key factors in optimizing patient care in Canada.</p>","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-8"},"PeriodicalIF":2.9,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hugh J McMillan, Hernan Gonorazky, Craig Campbell, Nicolas Chrestian, Megan Crone, James J Dowling, Kristina Joyal, Hanna Kolski, Ed Leung, Alex Mackenzie, Jean K Mah, Laura McAdam, Elisa Nigro, Cam-Tu Nguyen, Maryam Oskoui, Chantal Poulin, Jordan Sheriko, Mark Tarnopolsky, Jiri Vajsar, Amanda Yaworski, Kathryn Selby
{"title":"Equitable Access to Disease-Modifying Therapies for Canadian Children with SMA and Four <i>SMN2</i> Copies.","authors":"Hugh J McMillan, Hernan Gonorazky, Craig Campbell, Nicolas Chrestian, Megan Crone, James J Dowling, Kristina Joyal, Hanna Kolski, Ed Leung, Alex Mackenzie, Jean K Mah, Laura McAdam, Elisa Nigro, Cam-Tu Nguyen, Maryam Oskoui, Chantal Poulin, Jordan Sheriko, Mark Tarnopolsky, Jiri Vajsar, Amanda Yaworski, Kathryn Selby","doi":"10.1017/cjn.2024.319","DOIUrl":"10.1017/cjn.2024.319","url":null,"abstract":"","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-3"},"PeriodicalIF":2.9,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Estelle Gouriou, Mélanie Bourque, Cyril Schneider, Thérèse Di Paolo
{"title":"Exploring Magnetic and Electrical Brain Stimulation in Parkinsonian Dyskinetic Monkeys.","authors":"Estelle Gouriou, Mélanie Bourque, Cyril Schneider, Thérèse Di Paolo","doi":"10.1017/cjn.2024.284","DOIUrl":"https://doi.org/10.1017/cjn.2024.284","url":null,"abstract":"<p><strong>Background: </strong>Parkinson's disease (PD) chronic L-Dopa treatment often triggers motor complications, such as L-Dopa-induced dyskinesias (LID). LID are reported to be associated with abnormal glutamatergic activity between the striatum and primary motor cortex (M1), resulting in M1 hyperactivation. Beneficial noninvasive brain stimulation (NIBS) paradigms were reported to normalize glutamatergic activity. The objective of the present study was thus to set up a NIBS paradigm in parkinsonian monkeys to investigate motor behavior under basal conditions and with L-Dopa treatment-inducing dyskinesias.</p><p><strong>Methods: </strong>Motor behavior was investigated in five 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) dyskinetic female <i>Macaca fascicularis</i> monkey models of PD, allowing us to monitor the administration of NIBS and drugs. NIBS used were inhibitory protocols, that is, cathodal transcranial direct current stimulation (c-tDCS) and continuous theta-burst stimulation (cTBS). A procedure of three weeks was developed to progressively acclimate animals to the experimental conditions, equipment and noise of c-tDCS and cTBS before stimulating them with either vehicle or L-Dopa.</p><p><strong>Results: </strong>One session of c-tDCS with L-Dopa yielded no effect, whereas five sessions briefly reduced LID but decreased the duration of L-Dopa anti-PD effects. cTBS alone improved (decreased) parkinsonian scores as compared to sham stimulation or vehicle alone. Two sessions of cTBS with L-Dopa decreased LID without affecting L-Dopa anti-PD effects.</p><p><strong>Conclusion: </strong>This is the first study testing c-tDCS and cTBS on the motor behavior of MPTP dyskinetic monkeys. As compared to medicated patients, MPTP monkeys offer the opportunity to evaluate NIBS after-effects in drug-free and LID conditions, which are critical in the search for new PD treatment.</p>","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-12"},"PeriodicalIF":2.9,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jian-Qiang Lu, Gloria Mak, Sandra Grant, Steven K Baker
{"title":"Hereditary Transthyretin Amyloidosis Neuropathy with Intracellular Amyloidosis and Inclusions.","authors":"Jian-Qiang Lu, Gloria Mak, Sandra Grant, Steven K Baker","doi":"10.1017/cjn.2024.327","DOIUrl":"https://doi.org/10.1017/cjn.2024.327","url":null,"abstract":"","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-3"},"PeriodicalIF":2.9,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Wall-Eyed Internuclear Ophthalmoplegia: History and Hypothesis.","authors":"Janine L Johnston, James A Sharpe","doi":"10.1017/cjn.2024.317","DOIUrl":"https://doi.org/10.1017/cjn.2024.317","url":null,"abstract":"<p><strong>Background: </strong>Most patients with internuclear ophthalmoplegia (INO) are orthotropic, although a subset is exotropic. When INO is bilateral, this is termed wall-eyed bilateral internuclear ophthalmoplegia (WEBINO). In 1979, Sharpe described his \"first case\" of wall-eyed monocular internuclear ophthalmoplegia (WEMINO) as \"a unique clinical syndrome\" characterized by unilateral INO and ipsilateral exotropia.</p><p><strong>Methods: </strong>WEMINO was clinically identified in seven patients, with oculographic correlation in six and neuropathological confirmation in one. Oculographic features of exotropic INO patients were compared with those of six orthotropic INO patients using magnetic search coil and infrared oculography.</p><p><strong>Results: </strong>All clinically defined WEMINO patients showed slowed, hypometric ipsilateral saccades by oculography. Six patients had ipsilateral exotropia, and three had ipsilateral hypertropia. Ipsilateral abducting saccades had faster peak velocities for smaller saccades, more so for orthotropic patients. Exotropic patients had normal sinusoidal mean vestibulo-ocular reflex (VOR) gains and phases; orthotropic patients had subnormal mean VOR gains and phase leads.</p><p><strong>Conclusion: </strong>WEMINO is a clinical ocular motor syndrome characterized by unilateral slow, hypometric adducting saccades with exotropia and hypertropia of the ipsilateral eye. We propose that it results from discrete unilateral damage to burst-tonic fibers in the medial longitudinal fasciculus (MLF) with sparing of the adjacent extrafascicular pathways. Paradoxically, orthotropic INO results from more extensive damage to ascending pathways lateral, ventral and caudal to the MLF. Direct injury to the medial rectus subnucleus is not required. This manuscript was in preparation at the time of Dr Sharpe's death in 2013 and is an acknowledgement of his forward-thinking, as his hypotheses have stood the test of time.</p>","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-9"},"PeriodicalIF":2.9,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thalia S Field, Liqi Shu, Diana J Kim, Piers Klein, James E Siegler, Mary Cushman, Lily W Zhou, Thanh N Nguyen, Shadi Yaghi
{"title":"Lead-In Parenteral Anticoagulation Prior to Direct Oral Anticoagulation for Cerebral Venous Thrombosis.","authors":"Thalia S Field, Liqi Shu, Diana J Kim, Piers Klein, James E Siegler, Mary Cushman, Lily W Zhou, Thanh N Nguyen, Shadi Yaghi","doi":"10.1017/cjn.2024.325","DOIUrl":"https://doi.org/10.1017/cjn.2024.325","url":null,"abstract":"<p><strong>Background: </strong>Growing evidence suggests that direct oral anticoagulants (DOACs) may be suitable for cerebral venous thrombosis (CVT). The optimal strategy regarding lead-in parenteral anticoagulation (PA) prior to DOAC is unknown.</p><p><strong>Methods: </strong>In this post hoc analysis of the retrospective ACTION-CVT study, we compared patients treated with DOACs as part of routine care: those given \"very early\" DOAC (no PA), \"early\" (<5 days PA) and \"delayed\" (5-21 days PA). We compared baseline characteristics and outcomes between the very early/early and delayed groups. The primary outcome was a composite of day-30 CVT recurrence/extension, new peripheral venous thromboembolism, cerebral edema and intracranial hemorrhage.</p><p><strong>Results: </strong>Of 231 patients, 11.7% had very early DOAC, 64.5% early (median [IQR] 2 [1-2] days) and 23.8% delayed (5 [5-6] days). More patients had severe clinical/radiological presentations in the delayed group; more patients had isolated headaches in the very early/early group. Outcomes were better in the very early/early groups (90-day modified Rankin Scale of 0-2; 94.3% vs. 83.9%). Primary outcome events were rare and did not differ significantly between groups (2.4% vs. 2.1% delayed; adjusted HR 1.49 [95%CI 0.17-13.11]).</p><p><strong>Conclusions: </strong>In this cohort of patients receiving DOAC for CVT as part of routine care, >75% had <5 days of PA. Those with very early/early initiation of DOAC had less severe clinical presentations. Low event rates and baseline differences between groups preclude conclusions about safety or effectiveness. Further prospective data will inform care.</p>","PeriodicalId":56134,"journal":{"name":"Canadian Journal of Neurological Sciences","volume":" ","pages":"1-6"},"PeriodicalIF":2.9,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142633598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}